| scholarly article | Q13442814 |
| P5530 | Altmetric DOI | 10.1007/S10120-015-0502-3 |
| P6409 | CORE ID | 81901331 |
| P6179 | Dimensions Publication ID | 1022474677 |
| P356 | DOI | 10.1007/S10120-015-0502-3 |
| P953 | full work available at URL | http://eprints.whiterose.ac.uk/105720/ |
| P6366 | Microsoft Academic ID | 348142622 |
| P932 | PMC publication ID | 4824804 |
| P698 | PubMed publication ID | 25987463 |
| P5875 | ResearchGate publication ID | 277087624 |
| P1154 | Scopus EID | 2-s2.0-84929687537 |
| P50 | author | Megumi Hara | Q40354801 |
| Heike Irmgard Grabsch | Q47490153 | ||
| P2093 | author name string | Fuminori Moriyasu | |
| Kazuma Fujimoto | |||
| Jun Matsubayashi | |||
| Takao Itoi | |||
| Takuji Gotoda | |||
| Takayoshi Tsuchiya | |||
| Chika Kusano | |||
| Naoyuki Tominaga | |||
| Shin Kono | |||
| Matthew D Hale | |||
| P2860 | cites work | Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. | Q50999355 |
| HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. | Q52848050 | ||
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 | ||
| Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. | Q53645618 | ||
| Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. | Q54559293 | ||
| Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. | Q54574338 | ||
| HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. | Q54587084 | ||
| [WHO Classification of digestive tumors: the fourth edition] | Q82351087 | ||
| Japanese classification of gastric carcinoma: 3rd English edition | Q84106763 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 | ||
| HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer | Q34638138 | ||
| Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34656353 | ||
| HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. | Q35047997 | ||
| Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population | Q36897947 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P304 | page(s) | 553-560 | |
| P577 | publication date | 2015-05-19 | |
| P1433 | published in | Gastric Cancer | Q15724608 |
| P1476 | title | Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer | |
| P478 | volume | 19 |
| Q40619773 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications |
| Q33922534 | Clinical impact of tumour biology in the management of gastroesophageal cancer |
| Q98159085 | Comparing human epidermal growth factor receptor 2 amplification and expression using immunohistochemistry and silver in situ hybridisation in gastric carcinoma and lymph node metastasis |
| Q39363485 | Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis |
| Q99622843 | Gastric cancer |
| Q26741253 | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice |
| Q39174711 | HER2 testing in gastric cancer: results of a German expert meeting |
| Q57294534 | Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells |
| Q89303203 | Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples |
| Q88914440 | Identification of An mtDNA Setpoint Associated with Highest Levels of CD44 Positivity and Chemoresistance in HGC-27 and MKN-45 Gastric Cancer Cell Lines |
| Q28077666 | Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives |
| Q33733858 | Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer |
| Q53073585 | [HER2 testing in gastric cancer : Results of a meeting of German experts]. |
Search more.